Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NX1110TR | Other Identifier | company internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This registry study is national, multi-center, prospective study without any interventions to the treatment strategies and/or decisions of the investigators. It is designed in order to determine the general profile of HCC patients in Turkey. Socio-demographic characteristics, family history, medical history and treatment pattern of HCC patients will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Intervention | Other | All treatment options (inc. surgery, TACE, drugs) will be registered. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Descriptive analysis of HCC risk factors | i.e. smoking and alcohol consumption status; family history for hepatitis, HCC, and other malignancies; history of hepatic disease and blood transfusion; concomitant diseases; treatments applied | Baseline |
| Descriptive analysis of clinical profile of newly diagnosed HCC patients | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with underlying liver disease and family history | Baseline | |
| Treatment options as applied by doctors to HCC patients | Up to approximately 5 years | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients that are diagnosed with hepatocellular carcinoma in last 3 months
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Multiple Locations | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Overall survival time since diagnosis |
| Up to approximately 5 years |
| Number of participants with adverse events | Up to approximately 5 years |
| Descriptive analysis of demographic characteristics of HCC patients | Baseline |
| Descriptive analysis of clinical characteristics of HCC patients | Up to approximately 5 years |
| Descriptive analysis of tumor properties | Up to approximately 5 years |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |